Listed pharmas reduces R&D investments to overcome weakened profitability
Since some pharmaceutical companies’ profitability has been weakened, their short-sighted business management, which decreases investments in R&D, has been criticized.
According to the analysis result of the KOSPI and KOSDAQ listed pharmaceutical companies’ 2015 3rd quarter performances, their R...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
